Developing proteins to inhibit virus replication
Inhibition of virus replication by broadly-acting recombinant enhanced antiviral restrictors (REAVRs)
This study is exploring new proteins that could help fight off different viruses that can jump from animals to humans, aiming to find better ways to prevent these illnesses, especially those spread by mosquitoes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11101480 on NIH RePORTER |
What this research studies
This research focuses on creating innovative proteins called Recombinant Enhanced Antiviral Sensors (REAVRs) that can broadly inhibit various known and emerging viruses responsible for zoonotic diseases. By combining different virus-sensing and antiviral protein domains, the researchers aim to enhance the effectiveness of these proteins against viral infections. The project will involve testing these proteins in laboratory settings and understanding their effects on virus replication in cultured cells and mosquito models. This approach could lead to new strategies for controlling vector-borne viral diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk of zoonotic viral infections, particularly those living in areas where such diseases are prevalent.
Not a fit: Patients who are not at risk of zoonotic viral infections or those with existing viral infections that are not vector-borne may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral treatments that effectively prevent or control viral infections transmitted by mosquitoes and other vectors.
How similar studies have performed: Other research has shown promise in using similar recombinant protein strategies to combat viral infections, indicating potential for success in this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Rothenburg, Stefan — University of California at Davis
- Study coordinator: Rothenburg, Stefan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.